Skip to content
StockMarketAgent
Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

MLYS stock hub

Mineralys Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

MLYSis not in this month’s coverageGet our monthly research letter — no spam
Fair value midpoint
n/a
Fair value pending
Upside to midpoint
n/a
Based on latest report
Confidence
n/a
Data quality and model convergence
Market cap
2.4B
NASDAQ
Market data

Live price

Current market quote for this ticker.

Current price
MLYS
In the news

Latest news · MLYS

Recent company headlines from major financial publishers.

Loading
Fetching the latest headlines.
Loading
Fetching the latest headlines.
Loading
Fetching the latest headlines.
Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming
DateLoading
Window
EPS estimate
Revenue estimate
Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a
P25 12.3P50 18.4P75 33.1
Trailing P/En/a
P25 14.9P50 23.2P75 38.5
ROE-31
P25 -105.6P50 -46.5P75 -3.1
ROIC-21.9
P25 -63.1P50 -27.3P75 0.5
Benchmarks - 1M
S&P 500n/a
Nasdaq Compositen/a
Dow Jones Industrial Averagen/a
Russell 2000n/a
Indicator catalog

All MLYS market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields
176
Groups with data
11
Currency
USD
Showing 176 of 176 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

24
MetricValue
Cik
0001933414
Company name
Mineralys Therapeutics, Inc.
Country
United States
Country code
US
Cusip
603170101
Employees
76
Employees Change
25%
Employees Change Percent
49.02
Enterprise value
$1.8B
Exchange
NASDAQ
Financial currency
USD
First seen
2026-05-09
Industry
Biotechnology
IPO Date
2023-02-10
Isin
US6031701013
Last refreshed
2026-05-10
Market cap
$2.4B
Market cap category
Mid-Cap
Price
$29.54
Price currency
USD
Sector
Healthcare
Sic
2834
Symbol
MLYS
Website
https://mineralystx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

3
MetricValue
Earnings Yield
-6.23%
FCF yield
-5.6%
P/B ratio
3.82x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

10
MetricValue
Net Income
$-151.8M
Net Income Growth Quarters
3%
Net Income Growth Years
1%
Profit Per Employee
$-2M
ROA
-21.27
Roa5y
-64.6
ROCE
-26.87
ROE
-30.98
Roe5y
-356.5
ROIC
-21.88

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

5
MetricValue
Cagr1y
100.23%
Cagr3y
23.53%
EPS Growth Quarters
4
EPS Growth Years
1
Revenue Growth Years
0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

15
MetricValue
Assets
$652.9M
Cash
$646.1M
Current Assets
$652.5M
Current Liabilities
$14.7M
Equity
$638.1M
Liabilities
$14.7M
Long Term Assets
$392,000
Long Term Liabilities
$0
Net Cash
$646.1M
Net Cash By Market Cap
$26.51
Net Cash Growth
88.34%
Net Debt Equity
$-1.01
Tangible Book Value
$638.1M
Tangible Book Value Per Share
$7.74
WACC
6.9

Liquidity

Current-asset coverage and working-capital efficiency metrics.

4
MetricValue
Current ratio
44.33
Net Working Capital
$-8.3M
Quick ratio
43.9
Working Capital
$637.8M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

2
MetricValue
Buyback Yield
-48.35%
Dividend Yield
0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

36
MetricValue
1Y total return
100.14%
200-day SMA
31.39
3Y total return
88.51%
50-day SMA
27.21
50-day SMA vs 200-day SMA
50under200
All Time High
47.65
All Time High Change
-38.01%
All Time High Date
2025-11-12
All Time Low
5.85
All Time Low Change
404.96%
All Time Low Date
2023-11-22
ATR
1.82
Beta
0.48
Beta1y
1.08
Beta2y
1.22
Ch YTD
-18.6
High
30
High52
47.65
High52 Date
2025-11-12
High52ch
-38.01%
Low
28.57
Low52
12.59
Low52 Date
2025-08-13
Low52ch
134.63%
Ma50ch
8.56%
Price vs 200-day SMA
-5.88%
RSI
56.69
RSI Monthly
57.75
RSI Weekly
50.19
Sharpe ratio
1.02x
Sortino ratio
3.09
Total Return
-48.35%
Tr YTD
-18.6
Tr1m
4.35%
Tr1w
0.96%
Tr3m
-0.77%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

10
MetricValue
Analyst Count
7
Analyst Count Top
4
Analyst Price Target Top
$53.5
Analyst Ratings
Strong Buy
Analyst Ratings Top
Strong Buy
Earnings EPS Estimate
$-0.45
Operating Income
$-171.5M
Price target
$48.67
Price Target Change
$64.76
Price Target Change Top
$81.11

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

10
MetricValue
Float
60,359,044%
Float Percent
73.16%
Shares Insiders
0.81%
Shares Institutions
86.09%
Shares Out
82,498,101
Shares Qo Q
2.84%
Shares Yo Y
48.35%
Short Float
14.54%
Short Ratio
6.15
Short Shares
10.64

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

57
MetricValue
Adjusted FCF
$-158.6M
Average Volume
1,098,871.45x
Bv Per Share
7.74
CAPEX
$-15,000
Ch1m
4.35
Ch1w
0.96
Ch1y
100.1
Ch3m
-0.77
Ch3y
88.51
Ch6m
-22.3
Change
0.65%
Change From Open
1.44
Close
29.35
Days Gap
-0.78
Depreciation Amortization
50,000
Dollar Volume
26,434,459.8
Earnings Date
2026-05-06
Earnings Time
amc
EBIT
$-171.5M
EBITDA
$-171.4M
EPS
$-2.02
F Score
2
FCF
$-136.4M
FCF EV Yield
-7.62x
FCF Per Share
$-1.65
Financing CF
425,992,000
Fiscal Year End
December
Founded
2,019
Investing CF
-341,820,000
Ipr
84.63
Iprfo
40
Is Primary Listing
1
Is Spac
No
Last Earnings Date
2026-05-06
Last Report Date
2026-03-31
Last Split Type
Never
Last10k Filing Date
2026-03-12
Ma150
33.59
Ma150ch
-12.06%
Ma20
28.61
Ma20ch
3.27%
Net CF
-52,228,000
Next Earnings Date
2026-08-11
Open
29.12
Optionable
Yes
Position In Range
67.83
Post Close
29.54
Postmarket Change Percent
1.96
Postmarket Price
$30.12
Ppne
32,000
Price Date
2026-05-08
Ptbv Ratio
3.82
Relative Volume
0.81x
Share Based Comp
22,227,000
Tr6m
-22.3%
Us State
Pennsylvania
Volume
894,870
Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate
n/a
Named kill scenarios are reviewed before any bullish rating can stand.
Moat score
n/a
Business quality stays separate from stock attractiveness.
Forward P/E
n/a
Valuation uses the full report model stack, not a single multiple.
Next action
Research pending
Final action steps are kept in the recommendation tab.
Income

Does MLYS pay a dividend?

Capital-return profile for this ticker.

Performance

MLYS stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

1Y total return
+100.1%
S&P 500 1Y: n/a
3Y total return
+88.5%
S&P 500 3Y: n/a
5Y total return
n/a
S&P 500 5Y: n/a
10Y total return
n/a
S&P 500 10Y: n/a
Ownership

Who owns MLYS?

Insider, institutional, and short-interest positioning.

Institutional ownership
+86.1%
Float: +73.2% of shares outstanding
Insider ownership
+0.8%
Stake held by company insiders. Higher generally signals alignment.
Short interest
+14.5%
6.2 days to cover
Y/Y dilution
+48.4%
Negative means the company is buying back shares.
Technical

MLYS momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)
56.7
Neutral momentum band
Price vs 200-day MA
-5.9%
50/200-day relationship not available
Beta (5Y)
0.48
Less volatile than the market
Sharpe ratio
1.02
Risk-adjusted return — higher is better; >1.0 is solid.
Questions

About MLYS

Hub-level FAQ points readers to the deeper analysis pages.

What is the current MLYS stock rating?

Mineralys Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full MLYS analysis?

The full report lives at /stocks/MLYS/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for MLYS?

The latest report frames MLYS around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the MLYS page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.